Home » Newsletters » BioWorld Science

BioWorld Science

July 18, 2022

View Archived Issues

Novel hemophilia A murine model to test IdeS proteinase efficacy

Coagulant Therapeutics presents preclinical data on CT-001

Sunshine Lake Pharma patents new chymotrypsin inhibitors

Novartis divulges new cGAS inhibitors

Janssen Pharmaceutica presents new Mcl-1 inhibitors

Pfizer describes new IL-2 production inhibitors

Merck & Co. synthesizes orexin OX2 receptor agonists

PCYOX1 identified as new target for antithrombotic therapy

Enterome and Nestle Health Science collaborate to tackle food allergies and IBD

Murine model shows fibrin alpha crosslinking impairment behind thromboembolism

Thrombogenic effects of allosteric SHP2 inhibitor SHP-099

Defective gamma fibrinogen crosslinking exacerbates liver injury

Spread of Y chromosome deficiency in myeloid cells with age promotes cardiac fibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...